low resolution using crystallographic methods.
The principal binding sites are located within subdomains IIA and IIIA. Preliminary studies suggest that an approach to increasing the in vivo efficacy of drugs which are rendered less effective or ineffective by virtue of their interaction with HSA, would be the use of competitive displacement in drug therapies and/or the development of a general inhibitor to the site within subdomain IIIA.
These findings also suggest that the facilitated transfer of various ligands across organ/circulatory interfaces'such as the liver, kidney, and brain may be associated with binding to the IIIA subdomain.
Although serum albumin plays several important roles as the major protein of the circulatory system, it has been suggested that the molecule's high affinity for low molecular weight ligands may be its principal (9), and digitoxin, in an independent but unknown location (3, 4) . other studies indicate, however, that digitoxin competes with salicylates and warfarin for a common binding site (2,10). In this paper we present our preliminary findings regarding the major binding locations on HSA for several pharmaceutical compounds.
At the current resolution of 4.0 A the primary binding pockets within IIA and IIIA _e cavities of approximately 8 A X 12 A X 18 A which are exposed to the solvent channels through an opening of -9-10 A in diameter.
Large, well-ordered side chains protrude into these binding pockets where they appear to play a major role in ligand binding through stacking interactions. The identity of these amino acid residues should become evident once the model is fit to the electron density at higher resolution. and metabolism of both essential and foreign small molecules. Given the unique structure of serum albumin and the following interesting observations: (i) there is an asymmetric charge distribution within the primary structure of HSA at pH 7, of -9, -8, and -2 for domains I, II, and III respectively, thus indicating a potential amphoteric nature, (ii) HSA has been shown to interact with the cell membrane thereby aiding in the delivery of certain molecules, e.g. thyroxine, to the cell (12), (iii) subdomain IIIA appears to be the primary binding site for a variety of molecules, (iv) serum albumin is implicated in the facilitated transfer of ligands across various organ/circulatory interfaces, such as the liver, intestine, kidney, and brain; it is tempting to speculate whether the serum albumins possess membrane spanning properties. If this were the case, one might expect that HSA would unfold at the hinge region between IIA and IIB allowing the more lipophylic tail (subdomains liB, IIIA, and IIIB) of HSA to span the membrane while the more polar head of the molecule (subdomains IA, IB, IIA) would remain on the surface of the membrane, thus releasing the bound ligands in subdomain IliA into the cell. Perhaps then, ligand binding within subdomain IIIA is'a prerequisite for the facilitated transfer of many endogenous and exogenous compounds at organ/circulatory interfaces.
As we continue to characterize the nature of bound ligands to serum albumin and correlate this information with a wealth of drug and ligand binding data in the literature; it will become possible to predict important displacement interactions for a variety of endogenous and exogenous ligands. Accordingly, this suggests that an approach to increasing the in vivo efficacy of drugs which are rendered less effective or ineffective by virtue of their interaction with HSA would be the use of competitive displacement in drug therapies and/or the development of a general inhibitor to the site within subdomain IIIA.
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